| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Biomarin Pharmaceutical Inc. (BMRN) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 15 sells. BMRN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 159.4K | $8.93M | - | |
| VP | 80.0K | $4.48M | - | |
| VP | 55.1K | $3.09M | - | |
| Dir | 49.4K | $2.77M | - | |
| Dir | 46.4K | $2.60M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 3, 2018 | Bienaime Jean Jacques68 | Chief Executive Officer | Sale+OE | 1,500 | $99.36 | $149,040.00 | -0.5% | |
| Sep 27, 2018 | Lawlis V Bryan53 | Director | Sale+OE | 2,150 | $97.93 | $210,549.50 | -10.1% | |
| Sep 14, 2018 | Davis George Eric64 | EVP, General Counsel | Sell | 2,216 | $99.45 | $220,385.90 | -1.0% | |
| Sep 13, 2018 | Meier Richard A | Director | Sale+OE | 3,000 | $99.24 | $297,722.00 | -1.8% | |
| Sep 13, 2018 | Davis George Eric64 | EVP, General Counsel | Sell | 12,000 | $99.57 | $1,194,840.00 | -13.8% | |
| Sep 5, 2018 | Heron Elaine J | Director | Sell | 1,000 | $96.94 | $96,935.00 | -2.3% | |
| Sep 4, 2018 | Bienaime Jean Jacques68 | Chief Executive Officer | Sale+OE | 1,500 | $98.16 | $147,240.00 | -0.5% | |
| Aug 28, 2018 | Lewis Alan | Director | Sale+OE | 7,500 | $99.11 | $743,327.00 | -15.0% | |
| Aug 27, 2018 | Meier Richard A | Director | Sale+OE | 2,000 | $100.12 | $200,235.40 | -2.8% | |
| Aug 27, 2018 | Fuchs Henry J | President, Worldwide R&D | Sell | 25,000 | $99.50 | $2,487,500.00 | -8.4% |